ChemoCentryx - CCXI Stock Forecast, Price & News

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CCXI shares. StockNews.com cut shares of ChemoCentryx from a "hold" rating to a "sell" rating in a research report on Tuesday, August 2nd. Canaccord Genuity Group began coverage on shares of ChemoCentryx in a report on Thursday, August 4th. They issued a "buy" rating and a $81.00 price target on the stock. Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price target on the stock. in a report on Friday. SVB Leerink lowered shares of ChemoCentryx from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $64.00 to $52.00 in a research note on Friday. Finally, HC Wainwright lowered shares of ChemoCentryx from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $101.00 to $52.00 in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $65.11.

ChemoCentryx Price Performance

ChemoCentryx stock traded down $0.24 during trading on Tuesday, reaching $50.65. The company had a trading volume of 200,205 shares, compared to its average volume of 2,944,299. The firm's 50-day simple moving average is $25.84 and its 200 day simple moving average is $24.58. ChemoCentryx has a 1-year low of $13.11 and a 1-year high of $50.90. The firm has a market capitalization of $3.61 billion, a PE ratio of -25.22 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.07 and a current ratio of 5.11.

Insider Activity at ChemoCentryx

In related news, CEO Thomas J. Schall sold 130,000 shares of ChemoCentryx stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total value of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ChemoCentryx news, CEO Thomas J. Schall sold 130,000 shares of the firm's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total value of $6,531,200.00. Following the transaction, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Susan M. Kanaya sold 46,298 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.17, for a total value of $2,322,770.66. Following the completion of the sale, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at approximately $4,581,373.89. The disclosure for this sale can be found here. In the last quarter, insiders have sold 197,725 shares of company stock valued at $9,835,159. 8.30% of the stock is owned by company insiders.